GRAIL, a fast-growing Galleri test maker, spun off from Illumina in June. The population-scale MCED screening test identifies 50+ types of cancer from a simple blood draw
What is covered in the Full Insight:
Introduction
Company Background and Spin-Off
Product Overview: Galleri Test
Financial Performance
Investment Risks and Conclusion
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.